These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10332533)

  • 41. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
    Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
    J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hodgkin lymphoma--ABVD regimen].
    Nagai H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():642-5. PubMed ID: 25831839
    [No Abstract]   [Full Text] [Related]  

  • 43. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?
    Basaran G; Agaoglu F; Basaran M
    J Clin Oncol; 2010 Sep; 28(27):e485-6; author reply e487. PubMed ID: 20606082
    [No Abstract]   [Full Text] [Related]  

  • 44. [Sarcoidosis-like reaction after treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's lymphoma].
    Torrent A; Navarro JT; Andreo FC; Ribera JM
    Med Clin (Barc); 2013 Aug; 141(3):134-5. PubMed ID: 23332624
    [No Abstract]   [Full Text] [Related]  

  • 45. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
    Brusamolino E; Lunghi F; Orlandi E; Astori C; Passamonti F; Baraté C; Pagnucco G; Baio A; Franchini P; Lazzarino M; Bernasconi C
    Haematologica; 2000 Oct; 85(10):1032-9. PubMed ID: 11025593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.
    Hunger SP; Link MP; Donaldson SS
    J Clin Oncol; 1994 Oct; 12(10):2160-6. PubMed ID: 7523608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
    J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
    Hoskin PJ; Lowry L; Horwich A; Jack A; Mead B; Hancock BW; Smith P; Qian W; Patrick P; Popova B; Pettitt A; Cunningham D; Pettengell R; Sweetenham J; Linch D; Johnson PW
    J Clin Oncol; 2009 Nov; 27(32):5390-6. PubMed ID: 19738111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up of survival in Hodgkin's lymphoma.
    Canellos GP; Niedzwiecki D; Johnson JL
    N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
    [No Abstract]   [Full Text] [Related]  

  • 52. [Results of the treatment of Hodgkin's disease stage III and IV using the ABVD and BACOP programs].
    Leszko B; Słomkowski M; Przybyszewska M; Apel D; Pawelski S
    Acta Haematol Pol; 1986; 17(3-4):81-90. PubMed ID: 2438894
    [No Abstract]   [Full Text] [Related]  

  • 53. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
    Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
    J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sensorineural hearing loss associated with vincristine treatment.
    Lugassy G; Shapira A
    Blut; 1990 Nov; 61(5):320-1. PubMed ID: 2271781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Life-threatening hyponatremia caused by vinblastine.
    Zavagli G; Ricci G; Tataranni G; Mapelli G; Abbasciano V
    Med Oncol Tumor Pharmacother; 1988; 5(1):67-9. PubMed ID: 2452936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metronidazole ototoxicity--report of two cases.
    Iqbal SM; Murthy JG; Banerjee PK; Vishwanathan KA
    J Laryngol Otol; 1999 Apr; 113(4):355-7. PubMed ID: 10474673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report.
    Ress BD; Gross EM
    Ann Otol Rhinol Laryngol; 2000 Apr; 109(4):435-7. PubMed ID: 10778901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia.
    Swanson DJ; Sung RJ; Fine MJ; Orloff JJ; Chu SY; Yu VL
    Am J Med; 1992 Jan; 92(1):61-8. PubMed ID: 1731511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine.
    Tibaldi C; Pazzagli I; Berrettini S; De Vito A
    Eur J Cancer; 1998 Jun; 34(7):1133-4. PubMed ID: 9849468
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.